EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines

Ayşegül Yıldız, Cristian Răileanu, Tim Beissert iD

Viruses · 25.03.2024 · 16 (4) · 503

DOI: 10.3390/v16040503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 25.03.2024. Verfasst von Ayşegül Yıldız und 2 weiteren Autor:innen. Beteiligte Einrichtung: TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Hauptthemen laut MEDLINE: Alphavirus, RNA, Viral, Vaccine Development. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Replicating RNA, including self-amplifying RNA (saRNA) and trans-amplifying RNA (taRNA), holds great potential for advancing the next generation of RNA-based vaccines. Unlike in vitro transcribed mRNA found in most current RNA vaccines, saRNA or taRNA can be massively replicated within cells in the presence of RNA-amplifying enzymes known as replicases. We recently demonstrated that this property could enhance immune responses with minimal injected RNA amounts. In saRNA-based vaccines, replicase and antigens are encoded on the same mRNA molecule, resulting in very long RNA sequences, which poses significant challenges in production, delivery, and stability. In taRNA-based vaccines, these challenges can be overcome by splitting the replication system into two parts: one that encodes replicase and the other that encodes a short antigen-encoding RNA called transreplicon. Here, we review the identification and use of transreplicon RNA in alphavirus research, with a focus on the development of novel taRNA technology as a state-of-the art vaccine platform. Additionally, we discuss remaining challenges essential to the clinical application and highlight the potential benefits related to the unique properties of this future vaccine platform.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlphavirusRNA, ViralVaccine DevelopmentAnimalsHumansAlphavirus InfectionsViral VaccinesVirus Replication

Stichwörter der Autor:innen

alphavirusesdefective interfering RNAself-amplifying RNAtrans-amplifying RNAtrans-repliconvaccine

Substanzen

RNA, ViralViral Vaccines

Autor:innen und Institutionen

  • TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

ORCID-Profile: Tim Beissert

Zitieren

APA

Yıldız, A., Răileanu, C., & Beissert, T. (2024). Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines. Viruses, 16(4), 503. https://doi.org/10.3390/v16040503

Vancouver

Yıldız A, Răileanu C, Beissert T. Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines. Viruses. 2024;16(4):503. doi:10.3390/v16040503

BibTeX
@article{Yldz2024,
  author = {Yıldız, Ayşegül and Răileanu, Cristian and Beissert, Tim},
  title = {Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {503},
  doi = {10.3390/v16040503}
}
Kostenlos starten →